Literature DB >> 11244311

Low molecular weight heparin reduces proteinuria and modulates glomerular TNF-alpha production in the early phase of adriamycin nephropathy.

S Benchetrit1, E Golan, E Podjarny, J Green, G Rashid, J Bernheim, R Hershkovitz, J Bernheim.   

Abstract

BACKGROUND/AIM: Heparin has been shown to be renoprotective in a number of experimental nephropathies. The inflammatory component in the early phase of Adriamycin (ADR) induced nephropathy has been established. A microdose of low molecular weight heparin (Fragmin; F) has been noted to exert immunomodulatory effects independent of its anticoagulant activity. We assessed the effects of microdoses of F on daily proteinuria and glomerular production of tumor necrosis factor alpha (TNF-alpha) and prostaglandins 8 and 15 days after induction of ADR nephropathy.
METHODS: Following intravenous injection of ADR (7 mg/kg) to Wistar rats weighing 200 +/- 20 g, F 20 microg/day/rat s.c. was administered for 8 and 15 days (groups F8 and F15). The respective control groups (C8 and C15) received normal saline subcutaneously. Proteinuria, serum albumin, and creatinine clearance were evaluated on days 8 and 15. The production of TNF-alpha and prostaglandins from glomerular supernatants was measured by radioimmunoassay on days 8 and 15.
RESULTS: F significantly reduced proteinuria (mg/day) on day 8: 13.6 +/- 1.2 in F8 versus 40.3 +/- 2.7 in C8 (p = 0.008). The glomerular production of TNF-alpha (pi/ml) was significantly lower on day 8 in rats treated with F: 356 +/- 33 in F8 versus 764 +/- 81 in C8 (p = 0.006). A decrease in the prostaglandin E2/thromboxane B2 ratio was noted in the F group between 8 and 15 days (1.1 in F8 vs. 0.9 in F15, p = 0.005) which principally reflects an increase of thromboxane B2. The antiproteinuric effect of F shown after 8 days was no longer present after 15 days (354 +/- 91 mg/day in F15 vs. 499 +/- 69 mg/day in C15, p = 0.33). The same trend was seen for the glomerular production of TNF-alpha. Light microscopy and immunohistochemistry for interstitial and glomerular macrophages were negative.
CONCLUSION: The lowering effect of microdoses of F on the proteinuria seen during the early phase of ADR nephropathy may be mediated by a decreased production of glomerular TNF-alpha, supporting the anti-inflammatory action of low molecular weight heparin. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244311     DOI: 10.1159/000045905

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  5 in total

1.  Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.

Authors:  Ruchika Sharma; Amanda P Waller; Shipra Agrawal; Katelyn J Wolfgang; Hiep Luu; Khurrum Shahzad; Berend Isermann; William E Smoyer; Marvin T Nieman; Bryce A Kerlin
Journal:  J Am Soc Nephrol       Date:  2017-04-19       Impact factor: 10.121

2.  The efficiency of intraperitoneal high-dose immunoglobulin in experimental nephrotic syndrome.

Authors:  Seyhan Erisir; Halide Akbas; Mustafa Koyun; Sema Akman
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.714

Review 3.  The emerging role of coagulation proteases in kidney disease.

Authors:  Thati Madhusudhan; Bryce A Kerlin; Berend Isermann
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

4.  Beneficial effect of triple treatment plus immunoglobulin in experimental nephrotic syndrome.

Authors:  Sema Akman; Salih Kalay; Bahar Akkaya; Mustafa Koyun; Halide Akbaş; Yunus Emre Baysal; Ayfer Gur Guven
Journal:  Pediatr Nephrol       Date:  2009-02-18       Impact factor: 3.714

5.  Doxorubicin-induced renal inflammation in rats: Protective role of Plantago major.

Authors:  Nazanin Entezari Heravi; Sara Hosseinian; Zohreh Naji Ebrahimi Yazd; Mohammad Naser Shafei; Alireza Ebrahimzadeh Bideskan; Samira Shahraki; Zahra Samadi Noshahr; Fatemeh Motejadded; Farimah Beheshti; Reza Mohebbati; Soghra Parhizgar; Abolfazl Khajavi Rad
Journal:  Avicenna J Phytomed       Date:  2018 Mar-Apr
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.